1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64B4FA4A218D7A71100258A07003FB707
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-rare-disease-msl-team-excellence-benchmarking-roles-staffing-levels?OpenDocument
18
19OpenDocument
2044.200.27.215
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Rare Disease MSL Team Excellence: Benchmarking Roles and Staffing Levels

ID: 5770


Features:

10 Info Graphics

8 Data Graphics

80+ Metrics

7 Narratives


Pages/Slides: 23


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Rare Disease MSL Team Excellence: Benchmarking Roles and Staffing Levels”

STUDY OVERVIEW

As a strategic pillar within a rare disease organization, field medical teams are instrumental in fostering collaborative relationships with HCPs and KOLs. However, in a dynamic era of evolving responsibilities, rare disease field medical leaders must ensure their roles and expectations are well-aligned to best support stakeholders and deliver unparalleled value.

Best Practices, LLC undertook benchmarking research to establish current and emerging trends around managing virtual and hybrid medical science liaisons in rare diseases. This study will equip rare disease field medical leaders with the insights needed to optimize roles and staffing levels to ensure effective engagement.

KEY TOPICS

  • Rare Disease Staffing Levels: Traditional MSLs vs. Hybrid MSLs
  • Drivers of Rare Disease Field Team Evolution
  • Medical vs. Commercial Field Resourcing

KEY METRICS

  • How many MSLs and senior MSLs of each type (Traditional MSLs vs. Hybrid MSLs vs. Virtual MSLs) are currently staffed to the rare disease field team?
  • Average number of rare disease MSLs; MSL-to-senior MSL ratio at benchmark rare disease organizations
  • How effective are each of the listed MSL job roles in rare disease segment?
  • How critical have each of the listed factors been in shaping the current size and composition of roles within the rare disease field team?
  • Predicted changes in rare disease MSL staffing levels over the next 12-24 months
  • How many staff (FTEs) are currently allocated to the listed rare disease field team roles?

SAMPLE KEY FINDINGS

  • Field-based vs. Hybrid MSLs: Some 72% of organizations make use of traditional “field-based” MSLs, while another 56% use “hybrid” MSLs – but few organizations use both types in a strategically complementary manner. For many companies, the difference between field-based and hybrid MSLs is largely a semantic, as both types tend to operate in a similar manner.

METHODOLOGY

Best Practices, LLC engaged Field Medical and other Medical Affairs leaders from 22 top Rare Disease manufacturers in this research through a benchmark survey. Deep-dive interviews were also conducted with field medical leaders to capture additional insights.

Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical


Companies Profiled:
Alexion Pharmaceuticals; Amicus Therapeutics; Astellas; Bayer; Biogen; BioMarin; Bluebird Bio; Chiesi; CSL Behring; Dompé; Galapagos; Horizon Therapeutics; Ipsen; Kyowa Kirin; Novartis; Orchard Therapeutics; Sage Therapeutics; Servier; Supernus; Takeda Pharmaceuticals; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.